+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma

Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma

Leukemia and Lymphoma 33(5-6): 551-558

Serum levels of sICAM-1, sIL-2alphaR, and beta-2 microglobulin were measured in 63 patients with non-Hodgkin's lymphoma (NHL). The correlation between these serum markers as well as their relationship with NHL features and disease outcome were analyzed. Although in high-grade NHL sICAM-1 levels correlated with tumor mass, no correlation was found between sICAM-1 levels and tumor burden in low-grade NHL. When compared with sICAM-1 and beta-2 microglobulin, sIL-2alphaR showed the strongest correlation with the tumor burden. However, in multivariate analysis, including serum markers employed as continuous variables, the only parameteres which entered the regression model were beta-2 microglobulin (p=0.012) and sICAM-1 (p=0.019). In a dichotomized model, beta-2 microglobulin, aggressive histology, sICAM-1, age and number of nodal involved sites were found to be prognostically significant. Finally, by combining sICAM-1 and beta-2 microglobulin serum levels, a simple prognostic model useful for NHL was obtained.

(PDF emailed within 0-6 h: $19.90)

Accession: 045654457

Download citation: RISBibTeXText

PMID: 10342582

DOI: 10.3109/10428199909058459

Related references

Serum interleukin-6 and beta-2-microglobulin levels in aggressive lymphoma and in advanced multiple myeloma patients Correlation with disease activity and other prognostic parameters. Blood 86(10 SUPPL 1): 826A, 1995

Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma. Oncology 87(1): 40-47, 2014

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. Medical Oncology 31(9): 185, 2015

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget 7(44): 72219-72228, 2016

Importance of determination of serum beta-2-microglobulin levels in patients with Hodgkin's lymphoma. Vnitrni Lekarstvi 48(2): 91-95, 2002

Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers. British Journal of Haematology 92(3): 639-646, 1996

Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. British Journal of Haematology 88(4): 770-777, 1994

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leukemia Research 31(2): 139-145, 2006

The Levels of Serum C-Reactive Protein, Beta 2 Microglobulin, Ferritin, Lactate Dehydrogenase and Some Specific Proteins in Patients with Non-Hodgkin's Lymphoma Before and After Treatment. Eurasian Journal of Medicine 41(3): 165-168, 2009

Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. American Journal of Clinical Oncology 25(6): 570-572, 2002

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Annals of Oncology 13(12): 1908-1914, 2002

The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica 87(7): 701-8; Discussion 708, 2002

Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma. European Journal of Cancer and Clinical Oncology 19(3): 327-331, 1983

Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. Journal of Clinical Oncology 11(6): 1108-1111, 1993

beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. Journal of BUON 10(1): 59-69, 2007